SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Herceptin® in HER2 1+/2+ Breast Cancer Patients
April 02, 2018 08:40 ET
|
SELLAS Life Sciences Group
Clinically meaningful activity in favor of investigational nelipepimut-S (NeuVax) + Herceptin arm Clinically and statistically significant efficacy in triple negative breast cancer (TNBC) cohort;...
SELLAS Life Sciences Announces Appointment of Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary
March 21, 2018 08:45 ET
|
SELLAS Life Sciences Group
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
SELLAS Life Sciences’ Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting
March 19, 2018 08:45 ET
|
SELLAS Life Sciences Group
- Galinpepimut-S (GPS) induced immune activation against Wilms tumor-1 (WT1) antigen as well as multifunctional cross-epitope T-cell reactivity in patients with aggressive multiple myeloma -...
SELLAS Life Sciences Group Announces Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering Composition of Matter for WT-1 Peptides
March 15, 2018 08:45 ET
|
SELLAS Life Sciences Group
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on novel cancer...
SELLAS Life Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference
March 13, 2018 16:15 ET
|
SELLAS Life Sciences Group
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
SELLAS Life Sciences Announces $10,700,000 Private Placement
March 07, 2018 09:00 ET
|
SELLAS Life Sciences Group
- Financing Will Support Advancement of its Late-Stage Immuno-Oncology Pipeline - - Lead Candidate, Galinpepimut-S (GPS), On-Target for Initiation of Phase 3 Acute Myeloid Leukemia (AML) Study and...
SELLAS Life Sciences to Present at the 30th Annual ROTH Conference
March 05, 2018 16:15 ET
|
SELLAS Life Sciences Group
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
Data From SELLAS Life Sciences’ Positive Phase 2 Acute Myeloid Leukemia Study Published in American Society of Hematology’s Journal, Blood Advances
February 27, 2018 08:45 ET
|
SELLAS Life Sciences Group
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
SELLAS Life Sciences to Present at Two Upcoming February Investor Conferences
February 06, 2018 08:30 ET
|
SELLAS Life Sciences Group
- BIO CEO & Investor Conference on February 13 -- RBC Capital Markets Healthcare Conference on February 21 - NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc.,...
SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting
January 24, 2018 08:55 ET
|
SELLAS Life Sciences Group
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (SELLAS) today announced that an abstract highlighting the detailed description of antigen-specific immune...